Clinical Trial Update: Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating nivolumab in combination with sunitinib, pazopanib, or ipilimumab in metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)
• Sunitinib (sunitinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2019-08-02